Notice: Internet Explorer 11 users may encounter issues loading pages throughout the website. Please turn on IE-11’s compatibility mode while we work to resolve the issue.

>

MEETINGS / EVENTS

RSS

November 08 - 09 2014, 12:00 AM - 12:00 AM

ASA Quality Meeting 2014

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

>

FDA MEDWATCH ALERTS

October 16, 2014

FDA MedWatch - LifeCare Flexible Intravenous Solutions by Hospira, Inc.: Recall - Potential for Leakage

Summary:

FDA MedWatch LifeCare Flexible Intravenous Solutions by Hospira Inc

October 13, 2014

FDA MedWatch - CareFusion EnVe and ReVel Ventilators: Class 1 Recall - Power Connection Failure

Summary:

FDA MedWatch CareFusion EnVe and ReVel Ventilators

October 13, 2014

FDA MedWatch - ICU Medical ConMed Stat2 Flow Controller: Class 1 Recall - Delivers Higher Flow Rate than Intended

Summary:

FDA MedWatch ICU Medical ConMed Stat2 Flow Controller

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

Appeals Court Rules Against FDA in Sodium Thiopental Importation Case

Monday, July 29, 2013

On July 23, the United States Court of Appeals for the District of Columbia Circuit ruled in Cook v. Food and Drug Administration (FDA) that the FDA cannot permit importation of sodium thiopental into the United States because it is a misbranded and unapproved drug. 

Several prisoners on death row sued the FDA over the decision to permit state departments of correction to import sodium thiopental from overseas companies that are not registered with the FDA.  Sodium thiopental is used in lethal injection protocols.

According to the court's opinion, the FDA argued that "it must have discretion not to enforce § 381(a) in order to combat domestic shortages of medically necessary drugs."  The court disagreed and noted that the FDA has methods other than importation to counteract a drug shortage, such as working with manufacturers to increase production or mitigate quality problems. 

Public reports indicate the FDA is currently reviewing the court’s decision.  

ASA is also reviewing the opinion.

Review the opinion.

« Back to Washington Alerts